
European stock exchanges mull 24-hour trading to attract retail investors amid U.S. boom

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
21 minutes ago
- Business Wire
AEG Presents Elevates Jim King to Chief Executive Officer, AEG Presents UK and European Festivals
LONDON--(BUSINESS WIRE)--AEG Presents, a global leader in live entertainment, today announced that Jim King has been promoted to the role of Chief Executive Officer of AEG Presents UK and European Festivals. In addition, Steve Homer will transition to a new position as President, UK Touring at the company, as part of King's team. King, who was most recently CEO of European Festivals, will add oversight of the company's UK concert promotion business — from arena and stadium tours to club performances — to his remit. In his new role, Homer will focus on AEG Presents' UK touring business, leveraging his long-standing relationships and experience as one of the country's leading concert promoters. 'Jim's appointment is both a recognition of his achievements and a key strategic step as we continue aligning and expanding our UK and European business strategies,' said Adam Wilkes, President & CEO of AEG Presents Europe and Asia Pacific, to whom King will report. 'His vision and leadership have been central to shaping the company's presence and footprint across the region, and I'm confident that under his guidance we're well positioned for even greater success in the United Kingdom and across the continent. In addition, I'm thrilled that Steve will pivot to his new role, where he can focus on what he does best — bringing his talents as a gifted concert promoter to our newly realigned business.' Commented King: 'It's a privilege to take on this role at a time when the live entertainment landscape is evolving rapidly. AEG Presents has been my home for nearly 20 years now, and I've never been more excited about the opportunities ahead. I'm grateful to Adam and Jay Marciano [Chairman and CEO, AEG Presents] for their trust in me as we continue to build our business throughout the region with our extraordinary team, and I'm looking forward to working even more closely with Steve as we shape the future of our UK live event strategy.' From a formative start at Cream, where he produced the pioneering Creamfields festival, to launching celebrated events like RockNess and Bestival, King has long been at the forefront of live music innovation. Since joining AEG Presents in 2008, he has led the creation and production of flagship festivals including BST Hyde Park — featuring global superstars such as Adele, Elton John, Olivia Rodrigo, The Rolling Stones, Stevie Nicks, and Bruce Springsteen — and the eclectic All Points East, hosting acts like LCD Soundsystem, Mitski, Stormzy, and Chase & Status. King also oversees Rock en Seine in Paris and co-launched Bristol's Forwards Festival with Team Love in 2022. Most recently, 2025 saw the successful launch of LIDO in London's Victoria Park, further reinforcing his reputation for imaginative, sustainable, and community-driven programming. About AEG Presents Combining the power of the live event with a focus on true artist development, AEG Presents is a world leader in the music and entertainment industries. Operating across five continents, the company has an unparalleled commitment to artistry, creativity, and community. Its tentpole festivals and multi-day music events — which include the iconic Coachella Valley Music & Arts Festival and the legendary New Orleans Jazz & Heritage Festival alongside British Summer Time at Hyde Park, Stagecoach, Electric Forest, Rock en Seine and All Points East — continue to set the bar for the live music experience. AEG Presents promotes global tours for artists such as Justin Bieber, Zach Bryan, Sabrina Carpenter, Kenny Chesney, Luke Combs, Celine Dion, Elton John, Carin León, Paul McCartney, The Rolling Stones, Ed Sheeran, Taylor Swift, and Tyler, The Creator, in addition to — through its network of clubs, theatres, arenas, stadiums and renowned partner brands such as The Bowery Presents, Cárdenas Marketing Network, Concerts West, Frontier Touring, Goldenvoice, Marshall Arts, MCT Agentur, Messina Touring Group, PromoWest Productions, and Zero Mile Presents — creating and developing an unmatched infrastructure for artist development and audience reach. More information can be found at


CNBC
22 minutes ago
- CNBC
CCTV Script 23/07/2025
As the August 1st deadline approaches, the U.S. government is intensifying efforts to reach trade agreements with various countries. On Tuesday local time, progress was made in trade negotiations between the U.S. and Southeast Asian nations. According to the joint statement released by the White House, U.S. tariffs on Indonesia have been reduced from the previously threatened 32% in April to 19%. In return, Indonesia will lower tariffs to 0% on 99% of U.S. exports to Indonesia, covering sectors such as agricultural products, healthcare products, aquatic products, as well as communications technology, automobiles, and chemicals. In terms of tariff rates, the Special Adviser to the Indonesian President on International Trade said in an interview with CNBC that while the original 32% tariff level would have significantly impacted Indonesia's economy, the current 19% tariff is expected to shift the effect on GDP from a negative 0.6% to a positive growth of 0.5%. "We will be able to avoid, hopefully, the potential retrenchment in our labor intensive industries and exports, which have been the worst hit with the 32% tariff." It is worth noting that, according to the joint statement, Indonesia will comprehensively ease non-tariff barriers on U.S. industrial and agricultural products, including localization requirements, certification standards, import permits, and more. Specifically, Indonesia has agreed to exempt U.S.-invested companies and their products of origin from local content requirements. Previously, this policy was seen as a key measure to promote local employment in Indonesia, but it has now been relaxed. Secondly, Indonesia has agreed to adopt for American-made cars exported to Indonesia, which is also a positive development for U.S. automakers. Additionally, Indonesia will lift export restrictions on critical minerals. Moreover, overnight, Trump announced that the U.S. would impose a 19% tariff on the Philippines. This tariff adjustment follows a rise from 17% in April to 20% at the beginning of this month, and has now been reduced to 19%, matching the rate applied to Indonesia. According to U.S. government data, the U.S. trade deficit with the Philippines last year was $4.9 billion, with bilateral trade totaling $23.5 billion. In response to Trump's proposal for the Philippines to open its market to the U.S. and implement zero tariffs, the Philippines has yet to respond. Previously, the Philippines stated that it could not implement zero tariffs on U.S. goods like Vietnam and Indonesia, as it would harm the interests of domestic businesses. The president of the Philippine Exporters Confederation said in a CNBC interview that, based on a survey of local exporters, 10% of respondents reported their buyers were in a wait-and-see mode due to uncertainty about absorbing additional costs. However, most of these orders have already been successfully redirected to other markets. For Southeast Asian countries, they are closely monitoring the progress of trade negotiations between their neighbors and the U.S. This attention underscores the interconnected nature of regional trade dynamics and the potential ripple effects of bilateral agreements on neighboring economies. "We're really worried about the negotiations of our competitors. So sort of especially in the region. Because if what happens to Vietnam happens to the other countries here who have the same products with us, then we have a problem in the US, at least."


Hamilton Spectator
37 minutes ago
- Hamilton Spectator
Ipsen announces changes to its Executive Committee
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: Mari, Andreas and Caroline will report to Ipsen's Chief Executive Officer, David Loew, beginning September 1, 2025. After 4 years successfully leading the commercial operations for the International Region at Ipsen, Mari Scheiffele will now lead all medicines in Oncology and Rare Disease at Ipsen. In the new role, Mari will focus on driving product development and pipeline innovation for new medicines and lead globally, brands and life cycle management. Mari succeeds Bartek Bednarz who will now lead the newly created Asia, Pacific & China region at Ipsen. Andreas Gerber joins Ipsen from Johnson & Johnson where he most recently served as Worldwide Vice-president and Head of the Oncology Franchise. In his new role as Head of International, Andreas will lead Ipsen's operations in all geographies excluding North America. Andreas's extensive business acumen and commercial operations experience will support driving growth in Ipsen's three therapeutic areas: Oncology, Rare Disease and Neuroscience across the International region. Andreas succeeds Mari Scheiffele. Finally, Caroline Sitbon has been promoted to the role of Ipsen's General Counsel. Caroline joined the company from GSK in 2024 as Senior Vice President, Legal Affairs. In her new role, Caroline will lead legal and business ethics and will also serve as the Board of Directors' General Secretary. Caroline succeeds François Garnier who will be retiring after a very successful career, including his tenure as Ipsen's General Counsel and General Secretary to the Board of Directors. 'These three appointments bring additional highly qualified global leaders to our executive leadership team and I'm delighted that they represent a combination of internal promotions and new leaders that have joined Ipsen,' said David Loew, Chief Executive Officer. 'After personally working with both Mari and Caroline throughout their tenure at Ipsen, I have been impressed by their leadership, business insights and innovative mindsets. Each of these leaders, in their respective fields, have strongly contributed and partnered with Executive Leadership Team members to the ongoing transformation that we have been successfully driving at Ipsen. I am also very pleased to welcome Andreas to Ipsen. Over the last few years, I have observed his accomplishments and am convinced that his leadership and capacity to inspire our teams to execute and deliver on our strategy will be instrumental in our continuous growth trajectory in those respective markets. These additions also now represent a gender-balanced Executive Committee at Ipsen. I would also like to warmly thank François Garnier who had a long and distinguished career at Ipsen, making a big impact on the development of our company.' Mari Scheiffele said, 'I am honored to step into the role of Chief Product Officer at such an exciting time for our company. I am committed to driving innovation, fostering a culture of excellence, and continuing to work with our teams to deliver impact for our customers and patients.' Andreas Gerber said, 'I am thrilled to join Ipsen to lead the International Region and to work, together, with a world-class team to make a real impact on patients' everyday lives. I am looking forward to driving our innovative medicines across the portfolio to create access and adoption for patients and customers worldwide and to realize the full potential of our transformative therapies.' Caroline Sitbon added, 'It is an honor to take the General Counsel and General Secretary role and be part of this dynamic and fast-growing organization committed to advancing science for patients and consumers. I am very excited to have the opportunity to lead a highly qualified team that ensures our commitment to remain unwavering in compliance and integrity'. ABOUT IPSEN We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit . IPSEN CONTACTS Investors Khalid Deojee +33 6 66 01 95 26 Media Sally Bain +1 857 32 00 517 Anne Liontas +33 6 69 09 12 96 Disclaimers and/or Forward-Looking Statements The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on Attachment